Achieve Life Sciences Added to Russell 2000 Index
Event summary
- Achieve Life Sciences added to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026.
- $12.2 trillion in assets are benchmarked against the Russell U.S. Indexes as of June 30, 2025.
- Company focuses on developing cytisinicline for nicotine dependence treatment.
- Achieve has Breakthrough Therapy designation for vaping cessation indication.
The big picture
Achieve Life Sciences' inclusion in the Russell 2000 Index reflects growing institutional interest in small-cap biotech firms with promising pipelines. The move could enhance visibility and attract passive investment, though success hinges on regulatory approvals and commercial execution for its lead candidate, cytisinicline.
What we're watching
- Market Exposure
- How inclusion in the Russell 2000 will impact Achieve’s liquidity and investor base.
- Regulatory Progress
- The pace at which Achieve advances its NDA for cytisinicline in smoking cessation.
- Commercialization Strategy
- Whether Achieve can successfully launch and commercialize cytisinicline given its late-stage status.
Related topics